CD274 and hepatocellular carcinoma: Collectively, our findings highlight the potential of combining natural product BBR with other immunotherapies, providing a clinically translatable new strategy for HCC combination immunotherapy, particularly for anti-PD-L1 antibody treatment-resistant patient populations.